In the specialized landscape of neurodegenerative medicine, Amyotrophic Lateral Sclerosis (ALS) has long been viewed as a condition of reactive care. For decades, the focus was almost exclusively on managing symptoms as they manifested. However, the dawn of gene-targeted therapies has shifted the paradigm toward a proactive, precision-medicine approach. A new population modeling study, published in Neurology Genetics, warns that this shift—while medically revolutionary—is poised to create a massive logistical strain on the U.S. healthcare infrastructure.
As genetic testing becomes the standard of care for those with a family history of ALS, specialized centers across the country must prepare for a significant influx of both symptomatic patients and asymptomatic gene carriers. According to the projections, this surge will test the limits of clinic capacity, funding, and resource allocation by 2035.
The Core Data: A Decade of Expansion
The study, led by Jennifer Morganroth, MD, of Massachusetts General Hospital, provides a stark projection of the coming decade. By analyzing the prevalence of four primary gene variants—SOD1, C9orf72, FUS, and TARDBP—the research team established a baseline for current and future patient populations.
In 2026, the model estimates that 2,704 people in the United States are living with a symptomatic, gene-related form of ALS. Simultaneously, there are approximately 10,944 individuals categorized as asymptomatic gene carriers. These are the individuals who have tested positive for a pathogenic variant but have not yet shown clinical signs of the disease—a population that will require regular, long-term monitoring as preventive trials and early-intervention strategies evolve.
By 2035, the numbers are expected to accelerate dramatically. The symptomatic population is projected to grow to 7,474, while the number of asymptomatic carriers is expected to climb to 26,111. This nearly threefold increase represents a fundamental change in the patient demographic that ALS centers will be expected to manage.
Chronology: From Diagnosis to Proactive Monitoring
The trajectory of ALS care has moved rapidly since the early 2000s. Understanding the timeline of these developments is essential to grasp why the clinic visit surge is now unavoidable:
- Pre-2020: Genetic testing was largely reserved for research purposes or for those with a clear, dense family history. Care was primarily palliative and reactionary.
- 2023: The FDA approval of tofersen (Qalsody) served as the "Big Bang" for genetic ALS treatment. As an antisense oligonucleotide, it targets the mRNA responsible for SOD1 protein synthesis, offering the first real mechanism to slow the progression of a specific genetic form of the disease.
- 2024–2025: Consensus guidelines solidified, recommending that genetic testing be offered to all people with an ALS diagnosis, regardless of their family history. This policy shift has directly triggered a surge in the identification of gene carriers.
- 2026 (The Baseline): The current model uses 2026 as the reference point for calculating existing infrastructure stress. Currently, most states require fewer than 50 additional clinic visits annually per center to manage these patients.
- 2035 (The Projection): The model predicts a widespread shift in burden. Only six states are expected to maintain the "low burden" status of fewer than 50 annual visits. Meanwhile, 22 states will likely see 50 to 99 additional visits, 18 states will reach 100 to 199, and three states—likely those with larger aging populations or higher population density—will exceed 200 additional visits annually.
The Operational Strain: Infrastructure and Funding
The study’s findings arrive at a precarious moment for the neurology community. While the development of new drugs like the investigational jacifusen for FUS-ALS provides hope, the infrastructure required to deliver these treatments is currently under threat.
The Myth of Current Capacity
Morganroth and her colleagues note that while many clinics believe they are currently meeting the needs of their patient base, this is an illusion of stability. Most specialized ALS centers are operating at or near full capacity. Managing a patient with symptomatic ALS is labor-intensive, requiring multidisciplinary teams, including neurologists, physical therapists, speech-language pathologists, and social workers.
The Funding Crisis
The researchers explicitly highlight the "fragility of the current system." Recent funding cuts to major advocacy organizations—most notably the Muscular Dystrophy Association and the ALS Association—have created a financial vacuum. These organizations have historically served as the financial backbone for clinical trials and center operations. When these resources are restricted, the ability of a clinic to absorb a 20% to 50% increase in patient volume becomes not just a logistical challenge, but a systemic threat.
Official Perspectives: The Need for Strategic Planning
Dr. Morganroth’s statement accompanying the study emphasizes that the surge in patients is not a failure of medicine, but a success that must be managed. "As more at-risk relatives get genetic testing, the testing will identify more gene carriers, so specialized ALS centers must plan for the long-term care of more people," she stated.
The clinical implication is that care will shift from an episodic model to a longitudinal one. For asymptomatic carriers, this means regular biomarker monitoring, psychological support, and enrollment in preventive trials. "Anticipating the clinical needs of people with a genetic risk for ALS… is essential for improving care and ensuring that clinics are ready as new therapies become available," Morganroth added.
Implications: A Call to Action for the Healthcare Sector
The study offers a roadmap for what must change if the healthcare system is to survive this transition. The authors suggest several key areas for future development:
1. Dedicated Carrier Clinics
Rather than forcing asymptomatic carriers into the same workflow as symptomatic patients, the authors propose the creation of "dedicated carrier clinics." These units could focus on surveillance and preventive research, keeping the acute centers free for those in the advanced stages of the disease.
2. Telehealth-Based Surveillance
The geography of ALS care is inherently unequal. With patients often traveling hours to reach a specialized center, the model suggests that telehealth could be a primary tool for monitoring asymptomatic carriers. By shifting routine blood work or check-ins to local providers or home-based digital monitoring, centers could alleviate the physical strain on their clinics.
3. Integrating Data Sources
The study relied on a complex synthesis of Medicare, Veterans Health Administration, and census data. The authors advocate for a more integrated national database that tracks gene-positive cases, family mobility, and penetrance rates in real-time. Without a centralized data strategy, individual clinics will remain in the dark about their local patient surges until the patients arrive at their door.
4. Re-evaluating Funding Models
Given the potential for a massive, sustained increase in patient visits, the authors argue that current reimbursement models for ALS care may be insufficient. If the system is to remain sustainable, public and private insurance must recognize the unique, long-term costs of genetic ALS management, moving beyond the traditional fee-for-service model toward a capitated or value-based system that rewards long-term preventative care.
Methodological Limitations
It is important to view these projections through the lens of the researchers’ own caveats. The study utilized two complementary methods—one based on Atlanta-area demographic rates and the other on the National ALS Registry—to triangulate the data. However, the study does not account for de novo variants (new mutations that occur spontaneously) and assumes that patients will seek care in their home states.
Furthermore, the model assumes that only 7% of ALS cases are attributable to C9orf72, 2% to SOD1, 0.5% to FUS, and 0.4% to TARDBP. As genetic sequencing becomes more granular and widespread, these percentages may shift, potentially increasing the number of identifiable carriers. The researchers also acknowledged that their definition of an "ALS center" was limited to those listed in the I AM ALS directory, meaning there is a high likelihood that they have underestimated the total clinic burden by failing to include unaffiliated neuromuscular centers that may also be seeing these patients.
Conclusion: Preparing for the New Reality
The arrival of gene-targeted therapies represents the most significant breakthrough in ALS research since the disease was first described. However, the Neurology Genetics study serves as a necessary wake-up call. Medical progress does not exist in a vacuum; it requires a physical, financial, and logistical foundation.
If the United States is to fulfill the promise of precision medicine for ALS, the next decade cannot simply be about discovering new genes or testing new drugs. It must be about a wholesale expansion of clinical capacity. As the asymptomatic population grows, the medical community must pivot from being a collection of reactive treatment centers to a cohesive network of proactive, surveillance-based health systems. Failure to prepare for this influx will not only lead to logistical gridlock but will ultimately deny patients the very life-saving interventions that science is currently working so hard to produce.
